Correlation between genotype and phenotype of the human arylamine N- acetyltransferase type 1 (NAT1)

Biochemical Pharmacology

Volumn 58, Issue 11, 1999, Pages 1759-1764

  Bruhn, Claudia ^a   Brockmöller, Jürgen ^b   Cascorbi, Ingolf ^b   Roots, Ivar ^b   Borchert, Hans Hubert ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acetylation; Arylamine N acetyltransferase; NAT1; Pharmacogenetics; Phenotype; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; ENZYME KINETICS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

4-AMINOBENZOIC ACID; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; ERYTHROCYTES; GENOTYPE; HUMANS; ISOENZYMES; KINETICS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 0345240943     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00269-5     Document Type: Article

References (21)

1. Hein D.W., Doll M.A., Rustan T.D., Gray K., Feng Y., Ferguson R.J., Grant D.M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 13:1993;1633-1638.
2. Grant D.M., Hughes N.C., Janezic S.A., Goodfellow G.H., Chen H.J., Gaedigk A., Yu V.L., Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 376:1997;61-70.
3. Cascorbi I., Drakoulis N., Brockmöller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals Correlation with phenotypic activity . Am J Hum Genet. 57:1995;581-592.
4. Payton M.A., Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol. 55:1998;361-366.
5. Vatsis K.P., Martell K.J., Weber W.W. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA. 88:1991;6333-6337.
6. 560A mutations. Pharmacogenetics. 8:1998;67-72.
7. Deitz A.C., Doll M.A., Hein D.W. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem. 253:1997;219-224.
8. Lin H.J., Probst-Hensch N.M., Hughes N.C., Sakamoto G.T., Louie A.D., Kau I.H., Lin B.K., Lee D.B., Lin J., Frankl H.D., Lee E.R., Hardy S., Grant D.M., Haile R.W. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics. 8:1998;269-281.
9. Bell D.A., Badawi A.F., Lang N.P., Ilett K.F., Kadlubar F.F., Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue . Cancer Res. 55:1995;5226-5229.
10. Risch A., Smelt V., Lane D., Stanley L., van der Slot W., Ward A., Sim E. Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Pharmacol Toxicol. 78:1996;235-240.
11. Hughes N.C., Janezic S.A., McQueen K.L., Jewett M.A.S., Castranio T., Bell D.A., Grant D.M. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as in vivo and in vitro probe. Pharmacogenetics. 8:1998;55-66.
12. Ward A., Hickmann D., Gordon J.W., Sim E. Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 44:1992;1099-1104.
13. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen DNA-adduct formation in the human urinary bladder. Cancer Res. 55:1995;5230-5237.
14. Cribb A.E., Grant D.M., Miller M.A., Spielberg S.P. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther. 259:1991;1241-1246.
15. Grant D.M., Blum M., Beer M., Meyer U.A. Monomorphic and polymorphic human arylamine N-acetyltransferases A comparison of liver enzymes and expressed products of two cloned genes . Mol Pharmacol. 39:1991;184-191.
16. Cribb A.E., Tsui B., Isbrucker R., Michael R.T., Gillespie C.T., Brown-Bonomo J., Barrett P., Levatte T., Renton K.W. Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients. Br J Clin Pharmacol. 39:1995;85-89.
17. Derewlany L.O., Knie B., Koren G. Arylamine N-acetyltransferase activity of the human placenta. J Pharmacol Exp Ther. 269:1994;756-760.
18. Weber W.W., Vatsis K.P. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 3:1993;209-212.
19. Henning S., Cascorbi I., Münchow B., Jahnke V., Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 9:1999;103-111.
20. Vatsis K.P., Weber W.W., Bell D.A., Dupret J.M., Evans D.A.P., Grant D.M., Hein D.W., Lin H.J., Meyer U.A., Relling M.V., Sim E., Suzuki T., Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics. 5:1995;1-17.
21. Lindsay R.M., McLaren A.M., Baty J.D. Reversed-phase high performance liquid chromatographic assay for the determination of the in vitro acetylation of p-aminobenzoic acid by human whole blood. J Chromatogr. 433:1988;292-297.